JP Morgan Chase
ICCC icon

JP Morgan Chase’s ImmuCell ICCC Stock Holding History

JP Morgan Chase’s Portfolio ICCC Stock Details ICCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10
Closed -$48 – 7353
2025
Q1 		$48 Sell
10
-1
-9% -$5 ﹤0.01% 6990
2024
Q4 		$57 Hold
11
– – ﹤0.01% 7105
2024
Q3 		$40 Sell
11
-2
-15% -$8 ﹤0.01% 7156
2024
Q2 		$63 Hold
13
– – ﹤0.01% 6977
2024
Q1 		$69 Buy
13
+4
+44% +$21 ﹤0.01% 6969
2023
Q4 		$45 Buy
9
+2
+29% +$10 ﹤0.01% 7219
2023
Q3 		$36 Buy
+7
New +$36 ﹤0.01% 7051
2020
Q4 		– Sell
-4
Closed – – 5760
2020
Q3 		$0 Hold
4
– – ﹤0.01% 5601
2020
Q2 		$0 Buy
+4
New +$17 ﹤0.01% 5519

Other funds holding ICCC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SRC
Shufro Rose & Co New York $1.47B AUM 19.38% 1-Year Est. Return

JP Morgan Chase's ICCC Position: Q2 2025 in Review

JP Morgan Chase sold out of ImmuCell (ICCC) in Q2 2025, closing a stake of 10 shares — an estimated $48 sold.

JP Morgan Chase first reported a position in ICCC in Q2 2020 and held it in 9 quarters. The position peaked at $69 in Q1 2024. 25 funds tracked by Wall St. Rank hold ICCC as of Q2 2025.

  • JP Morgan Chase reported no remaining ImmuCell position as of Q2 2025 after selling out during the quarter.
  • JP Morgan Chase sold 10 ImmuCell shares in Q2 2025, an estimated $48.
  • JP Morgan Chase first reported a position in ImmuCell in Q2 2020 and held it in 9 quarters.
  • JP Morgan Chase's ImmuCell position peaked at $69 in Q1 2024.
  • 25 funds tracked by Wall St. Rank held ImmuCell as of Q2 2025.

Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.